Off-target mRNAs with seed-region complementarity to miATXN3-10x2

Off-target mRNAs with seed-region complementarity to miATXN3-10x2 refers to a collective group of unintended cellular transcripts that are susceptible to downregulation by the artificial microRNA (amiRNA) construct miATXN3-10x2. This amiRNA is the active component of AMT-150, a gene therapy candidate developed by uniQure for the treatment of Spinocerebellar Ataxia Type 3 (SCA3) (Martier et al., 2019). While miATXN3-10x2 is designed to specifically target the ATXN3 gene, it can also bind to other mRNAs that share complementary sequences to its seed region, typically nucleotides 2-8 of the guide strand (Evers et al., 2018). This binding usually occurs in the 3' untranslated region (UTR) of the off-target mRNAs, leading to their degradation or translational repression via the RNA-induced silencing complex (RISC). The identification and quantification of these off-target effects are crucial for assessing the safety profile of RNA interference-based therapeutics, as silencing essential genes could lead to cellular dysfunction or toxicity (uniQure, 2021). In preclinical development, these off-targets are monitored using high-throughput RNA sequencing and bioinformatics to ensure the specificity of the therapeutic construct. Because these molecules are unintended recipients of the drug's action, they represent a safety concern rather than a therapeutic target. The specific profile of affected mRNAs can vary depending on the tissue-specific transcriptome of the patient. Minimizing these interactions is a primary goal in the design of next-generation RNAi therapies. Overall, this entity describes a safety parameter used to evaluate the precision of the miATXN3-10x2 gene therapy.

Other names

miATXN3-10x2 off-targetsSeed-mediated off-targets of AMT-150miATXN3-10 off-targets

RNA interference-mediated gene silencing via seed-region complementarity leading to mRNA degradation or translational repression